University of Illinois Urbana-Champaign researchers reported in vivo CRISPR base editing that reduced toxic protein fragments and neurologic symptoms in a mouse model of Huntington’s disease. The approach modifies rather than silences the HTT gene by editing a splice acceptor in exon 13, designed to disrupt proteolysis into harmful N-terminal fragments. The work, published in Nature Biomedical Engineering, describes base editors intended to generate proteolysis-resistant HTT isoforms by forcing the cell to skip the targeted exon segment. In the study, researchers linked the gene-editing mechanism to reductions in toxic protein burden and associated symptom measures. The preclinical results add to a growing set of gene-editing strategies targeting downstream mutant protein processing, supporting a continued focus on precision edits that preserve gene function while neutralizing toxic fragment formation.